Gsa Capital Partners LLP Kronos Bio, Inc. Transaction History

Gsa Capital Partners LLP

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2024 May 03, 2024	BUY	$1.02 - $1.3 $32,845 - $41,861	32,201 Added 128.06%	57,347 $74,000
Q4 2023 Feb 16, 2024	SELL	$0.75 - $1.49 $22,031 - $43,768	-29,375 Reduced 53.88%	25,146 $31,000
Q3 2023 Nov 15, 2023	SELL	$1.23 - $2.25 $284,922 - $521,199	-231,644 Reduced 80.95%	54,521 $70,000
Q2 2023 Aug 14, 2023	SELL	$1.24 - $1.92 $149,044 - $230,778	-120,197 Reduced 29.58%	286,165 $492,000
Q1 2023 May 12, 2023	SELL	$1.34 - $2.62 $44,975 - $87,937	-33,564 Reduced 7.63%	406,362 $593,000
Q4 2022 Feb 13, 2023	BUY	$1.44 - $3.44 $412,178 - $984,648	286,235 Added 186.24%	439,926 $713,000
Q3 2022 Nov 14, 2022	BUY	$3.35 - $5.55 $223,930 - $370,989	66,845 Added 76.97%	153,691 $515,000
Q2 2022 Aug 09, 2022	BUY	$3.12 - $7.52 $135,046 - $325,495	43,284 Added 99.36%	86,846 $316,000
Q1 2022 May 11, 2022	BUY	$6.26 - $14.42 $272,698 - $628,164	43,562 New	43,562 $315,000

20.7M

31.4K

Ticker KRON
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 56,769,100
Market Cap $55.1M
Description
Kronos Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of novel cancer therapeutics. The company's product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks that drive oncogenic activity. Its lead product candidate is entospletinib (ENTO), is an orally...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.